Terms: = Liver cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
12 results:
1. Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for liver cancer.
Zecca A; Barili V; Olivani A; Biasini E; Boni C; Fisicaro P; Montali I; Tiezzi C; Dalla Valle R; Ferrari C; Cariani E; Missale G
Front Immunol; 2022; 13():875072. PubMed ID: 35677052
[TBL] [Abstract] [Full Text] [Related]
2. Lumican, pro-tumorigenic or anti-tumorigenic: A conundrum.
Appunni S; Rubens M; Ramamoorthy V; Anand V; Khandelwal M; Saxena A; McGranaghan P; Odia Y; Kotecha R; Sharma A
Clin Chim Acta; 2021 Mar; 514():1-7. PubMed ID: 33333043
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent erk signaling.
Liu H; Zhang Q; Li K; Gong Z; Liu Z; Xu Y; Swaney MH; Xiao K; Chen Y
Oncotarget; 2016 Dec; 7(49):81223-81240. PubMed ID: 27835898
[TBL] [Abstract] [Full Text] [Related]
4. High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.
Li HJ; Sun QM; Liu LZ; Zhang J; Huang J; Wang CH; Ding R; Song K; Tong Z
Oncol Rep; 2015 Aug; 34(2):795-802. PubMed ID: 26082242
[TBL] [Abstract] [Full Text] [Related]
5. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
6. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
[TBL] [Abstract] [Full Text] [Related]
7. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression.
Duan M; Wang ZC; Wang XY; Shi JY; Yang LX; Ding ZB; Gao Q; Zhou J; Fan J
Ann Surg Oncol; 2015 Sep; 22(9):3121-9. PubMed ID: 25465376
[TBL] [Abstract] [Full Text] [Related]
8. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression.
Wang FW; Cai MY; Mai SJ; Chen JW; Bai HY; Li Y; Liao YJ; Li CP; Tian XP; Kung HF; Guan XY; Xie D
Oncotarget; 2014 Aug; 5(16):6716-33. PubMed ID: 25071013
[TBL] [Abstract] [Full Text] [Related]
9. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract] [Full Text] [Related]
10. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection.
Xu YF; Yi Y; Qiu SJ; Gao Q; Li YW; Dai CX; Cai MY; Ju MJ; Zhou J; Zhang BH; Fan J
J Hepatol; 2010 Nov; 53(5):872-9. PubMed ID: 20739083
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
Frau M; Biasi F; Feo F; Pascale RM
Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
[TBL] [Abstract] [Full Text] [Related]
12. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.
Calvisi DF; Ladu S; Gorden A; Farina M; Lee JS; Conner EA; Schroeder I; Factor VM; Thorgeirsson SS
J Clin Invest; 2007 Sep; 117(9):2713-22. PubMed ID: 17717605
[TBL] [Abstract] [Full Text] [Related]
